surpass 2 tirzepatide versus Semaglutide in Type Diabetes (SURPASS-2) | NEJM Tirzepatide versus Semaglutide Once Weekly

The key message is clear: these treatments are powerful, but their long-term public health impact will depend on whether the right support systems are in place to ensure equitable and safe access for all patients. This comes as a new semaglutide 7.2mg single-dose pen has been launched by Novo Nordisk as a maintenance dose for adults with obesity, following approval from the Medicines and Healthcare products Regulatory Agency

These medications are generally well-tolerated, but the most common side effects include nausea, diarrhea, and sometimes mild indigestion

At the time the MDL was formed, at least 30 Ozempic vision-loss claims were consolidated into the federal group lawsuit

One missed session will not undo your progress